scholarly journals Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma

1997 ◽  
Vol 75 (2) ◽  
pp. 283-286 ◽  
Author(s):  
C Bain ◽  
Y Merrouche ◽  
I Puisieux ◽  
J-Y Blay ◽  
S Negrier ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Response ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Interleukin 2

Possible Correlation between Some Biologic Effects and the Clinical Course in Patiens Treated with Continuous Infusion of Interleukin-2 plus Alpha-2 Interferon for Metastatic Renal Cell Carcinoma

1994 ◽  
Vol 80 (5) ◽  
pp. 348-352 ◽  
Author(s):  
Claudia Baiocchi ◽  
Giuseppe Landonio ◽  
Gabriella Balzarmi ◽  
Carlo Cacioppo ◽  
Mario Calgaro ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Continuous Infusion ◽  
Clinical Response ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Complete Response ◽  
Antithyroid Antibodies ◽  
Biologic Effects

Background Interleukin-2 therapy is known to cause many biologic effects, which are enhanced by the administration of interferon prior to or immediately after interleukin-2 infusion. Some of these effects could be related to the clinical response. Methods Sixteen patients with metastatic renal cell carcinoma were treated with continuous infusion of interleukin-2 plus alpha-2 interferon. Differential leukocyte count and lymphocyte subset evaluation were performed every 3 days during interleukin-2 treatment. At each cycle, the presence of the following antibodies was tested: antithyroid, antinuclear, antiplatelet and antierythrocyte. Results Fifteen patients were evaluable for response. No complete response was observed. Five patients obtained partial response (33%) and 3 stable disease (20%): 2 of them underwent surgical resection of metastases and obtained complete response. Some of our patients showed a significant increase in eosinophils, CD25+ lymphocytes and antithyroid antibodies. The association of these parameters, calculated with a “score” system, was also related to a better clinical response. Conclusions Eosinophils, CD25+ lymphocytes and antithyroid antibodies could have a predictive value for the efficacy of interleukin-2 and alpha-2 interferon therapy in metastatic renal cell carcinoma.

scholarly journals Fas Ligand Expression in Metastatic Renal Cell Carcinoma During Interleukin-2 Based Immunotherapy

2004 ◽  
Vol 10 (23) ◽  
pp. 7911-7916 ◽  
Author(s):  
Frede Donskov ◽  
Hans von der Maase ◽  
Niels Marcussen ◽  
Stephen Hamilton-Dutoit ◽  
Hans Henrik Torp Madsen ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Fas Ligand ◽  
Interleukin 2 ◽  
Ligand Expression

scholarly journals A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma

2014 ◽  
Vol 37 (3) ◽  
pp. 180-186 ◽  
Author(s):  
Paul Monk ◽  
Elaine Lam ◽  
Amir Mortazavi ◽  
Kari Kendra ◽  
Gregory B. Lesinski ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Phase I ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase I Study ◽  
Interleukin 2 ◽  
High Dose

scholarly journals Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2

2016 ◽  
Vol 10 ◽  
Author(s):  
David M Gill ◽  
David D Stenehjem ◽  
Kinjal Parikh ◽  
Joseph Merriman ◽  
Arun Sendilnathan ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Interleukin 2 ◽  
High Dose ◽  
Conditional Survival

Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2

1997 ◽  
Vol 43 (5) ◽  
pp. 293-298 ◽  
Author(s):  
Rutger L. van Bezooijen ◽  
H. Goey ◽  
Gerrit Stoter ◽  
J. Hermans ◽  
G. J. Fleuren
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Prognostic Markers ◽  
Interleukin 2
Sign in / Sign up

Export Citation Format

Share Document